Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trialBruce Cree, Piotr Sokolowski, Eva Meluzínová et al.|The Lancet Neurology|2020Cited by 104
Expansion of chronic lesions is linked to disease progression in relapsing–remitting multiple sclerosis patientsSamuel Klistorner, Alexander Klistorner, Yuyi You et al.|Multiple Sclerosis Journal|2020Cited by 53
Expansion of chronic MS lesions is associated with an increase of radial diffusivity in periplaque white matterSamuel Klistorner, Alexander Klistorner, Yuyi You et al.|Multiple Sclerosis Journal|2021Cited by 13
Differentiating axonal loss and demyelination in chronic MS lesions: A novel approach using single streamline diffusivity analysisSamuel Klistorner, Alexander Klistorner, Yuyi You et al.|PLoS ONE|2021Cited by 10